| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.MPA.0000240275.68279.13 |
| P698 | PubMed publication ID | 17079944 |
| P50 | author | Yoichi Maekawa | Q41602195 |
| Tetsuya Ikemoto | Q79323460 | ||
| P2093 | author name string | Takeshi Yamaguchi | |
| Masahiko Fujii | |||
| Mitsuo Shimada | |||
| Satoru Imura | |||
| Yuji Morine | |||
| Koji Yasutomo | |||
| Yuji Soejima | |||
| P433 | issue | 4 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 386-390 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Pancreas | Q15762014 |
| P1476 | title | Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients | |
| P478 | volume | 33 |
| Q84459533 | Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms |
| Q84633735 | B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets |
| Q38857263 | CD4(+) T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4(+) T cells in pancreatic cancer development |
| Q92494636 | CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression |
| Q26777542 | Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction |
| Q35033249 | Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. |
| Q44618335 | Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer |
| Q47781860 | Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. |
| Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
| Q34093784 | Complex role for the immune system in initiation and progression of pancreatic cancer. |
| Q37346107 | Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors |
| Q40449073 | Expression of CXC chemokine receptor-4 and forkhead box 3 in neuroblastoma cells and response to chemotherapy. |
| Q34142307 | FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis |
| Q26765123 | From bench to bedside a comprehensive review of pancreatic cancer immunotherapy |
| Q37294755 | Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer |
| Q36957222 | Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer |
| Q39003009 | L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression |
| Q42106687 | Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells |
| Q28072712 | Monitoring of the Immune Dysfunction in Cancer Patients |
| Q92067766 | Myeloid derived suppressor cells are reduced and T regulatory cells stabilised in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega 3 |
| Q36896764 | Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer |
| Q37273138 | OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. |
| Q55080593 | Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. |
| Q40261599 | Pancreatic cancer: Update on immunotherapies and algenpantucel-L. |
| Q35886496 | Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy |
| Q33560501 | Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment |
| Q35870682 | Pancreatic ductal adenocarcinoma: a review of immunologic aspects |
| Q37861220 | Potential targets for pancreatic cancer immunotherapeutics |
| Q35739397 | Process of hepatic metastasis from pancreatic cancer: biology with clinical significance |
| Q41429144 | Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3+)/activated cytotoxic T lymphocyte (granzyme B+) ratio on resected left-sided pancreatic cancer |
| Q86124554 | Regulatory T cells in the blood: a new marker of surgical stress |
| Q37606102 | Role of immune cells in pancreatic cancer from bench to clinical application: An updated review |
| Q92307792 | The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective |
| Q36808542 | The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients |
Search more.